Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.

By A. Fukuhara, M. Matsuda, M. Nishizawa, Katsumori Segawa, Masaki Tanaka, Kae Kishimoto, Yasushi Matsuki, Mirei Murakami, T. Ichisaka, H. Murakami and 12 more. Science, 2005

1,311 citations recorded by the source corpus.

Subfields: Endocrine and Autonomic Systems, Epidemiology, Physiology

View Paper: https://www.semanticscholar.org/paper/e39b4ea0eb1e44a62a054eac5162cbce3088107f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrine and Autonomic Systems

1. Herbert Tilg
2. D. Sinclair
3. G. Frühbeck
4. A. Moschen

In Epidemiology

1. D. Sinclair
2. Herbert Tilg
3. A. Moschen
4. K. Walsh
5. Joseph A. Baur
6. J. Bastard
7. Myung‐Sook Choi
8. K. Petersen

In Physiology

1. D. Sinclair
2. Joseph A. Baur
3. S. Imai
4. Herbert Tilg
5. K. Walsh
6. Myung‐Sook Choi
7. K. Petersen
8. A. Kaser

Citations in the corpus

• Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin (2006, background): “The adipokines resistin and visfatin have been implicated in the modulation of insulin signalling in the liver in rodents [9, 10].”
• Inflammation, stress, and diabetes. (2005, neutral): “Adiponectin, resistin, and visfatin are also examples of molecules with immunological activity that are produced in adipocytes (22–26).”
• Inflammatory Mechanisms in the Regulation of Insulin Resistance (2008, background): “Visfatin was shown to mimic insulin activity by binding to the insulin receptor (62).”
• Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. (2007, methodology): “…weemployedseveraldifferentcellmodels: thehumanSGBS cell line; the mouse 3T3-L1 cell line that was also used in the original report of visfatin (Fukuhara et al., 2005); and R- and R-IR cells, mouse fibroblast cell lines in which the endogenous insulin-like growth factor 1 (IGF-1) receptor is…”
• Visfatin, an Adipocytokine with Proinflammatory and Immunomodulating Properties1 (2007, background): “Visfatin has been shown to bind to the IR and to mimic insulin action (8).”
• Mitochondrial dysfunction and type 2 diabetes (2005, background): “Although it is widely believed that adipocyte-derived cytokines that are released by the visceral fat, such as tumor necrosis factor-α [26], interleukin-6 [27], adiponectin [28], and visfatin [29,30], may be responsible for the insulin resistance in android-shaped individuals, an alternative explana”
• Adipokines: the missing link between insulin resistance and obesity. (2008, background): “On the other hand, growth ate, total body weight, food intake, and brown fat levels in uscle and heart are not different from wild-type mice [76].”
• Intracellular signalling pathways activated by leptin. (2006, background): “…central nervous system as well as in the periphery, such as resistin [162,163], ghrelin [164], adiponectin [165], peptide YY 3 − 36 [166], visfatin [167], vaspin (visceral adipose tissue-derived serine protease inhibitor) [168], endocannabinoids [169,170], aquaporin-7 [171] and FAT-ATTAC (fat…”
• NAD+/NADH and NADP+/NADPH in Cellular Functions and Cell Death: Regulation and Biological Consequences (2008, neutral): “Recent studies have indicated multiple novel and interesting properties of Nampt—-another key enzyme in NAD synthesis: it has been demonstrated that three seemingly different proteins—-Nampt, the presumptive cytokine pre-B-cell colony-enhancing factor (PBEF), and a new visceral fat-derived hormone v”
• Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease (2014, background): “Visfatin was highly expressed in the visceral adipose tissue of mice as well as humans, and treatment with visfatin enhances glucose uptake in adipocytes and myocytes [134].”
• The metabolic syndrome. (2008, background): “gree of visceral adiposity in humans (240) and has been”
• Mechanisms linking obesity with cardiovascular disease (2006, background): “Visfatin levels correlate strongly with an individual's amount of visceral fa”
• Adipokines as emerging mediators of immune response and inflammation (2007, background): “Visfatin Visfatin is an insulin-mimetic adipokine that was originally discovered in liver, skeletal muscle and bone marrow as a growth factor for B lymphocyte precursors (whence its alternative name, pre-B-colony enhancing factor, or PBEF)”